Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes
Open Access
- 1 May 1989
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 32 (5), 305-311
- https://doi.org/10.1007/bf00265547
Abstract
Many patients with Type 2 (non-insulin-dependent) diabetes mellitus are treated with insulin in order to control hyperglycaemia. We studied fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and 24 h urinary C-peptide in relation to clinical type of diabetes in 132 insulin treated diabetic subjects. Patients were classified clinically as Type 1 (insulin-dependent) diabetic subjects in the presence of at least two of the following criteria: 1) significant ketonuria, 2) insulin treatment started within one year after diagnosis, 3) age of diagnosis ≤40 years, and 4) weight below 110% of ideal weight of the same age and sex. Eighty patients were classified as Type 1 and 52 as Type 2 diabetic subjects. A second classification of patients into 6 C-peptide classes was then performed. Class I consisted of patients without islet B-cell function. Class II-VI had preserved islet B-cell function and were separated according to the 20%, 40%, 60% and 80% C-peptide percentiles. The two classifications of patients were compared by calculating the prevalence of clinical Type 1 and Type 2 diabetes in each of the C-peptide classes. This analysis showed that patients with a fasting plasma C-peptide value <0.20 nmol/l, a glucagon stimulated plasma C-peptide value <0.32 nmol/l, and a urinary C-peptide value <3.1 nmol/l, or <0.54 nmol/mmol creatinine/24 h, or <5.4 nmol/24 h mainly were Type 1 diabetic patients; while patients with C-peptide levels above these values mainly were Type 2. At these limits the percentage, predictive value of positive tests as indicators of Type 2 diabetes were as follows: fasting C-peptide 83%, stimulated C-peptide 86%, and urinary C-peptide expressed as nmol/l 76%, as nmol/mmol creatinine/24 h 79%, and as nmol/24 h 78%. Similarly, the percentage predictive value of negative tests as indicators of Type 1 diabetes were as follows: fasting C-peptide 86%, stimulated C-peptide 88%, and urinary C-peptide expressed as nmol/l 79%, as nmol· mmol creatinine·24 h 81%, and as nmol/24 h 80%. If patients without detectable C-peptide were excluded, the predictive value of negative tests were as follows: fasting C-peptide 81%, stimulated C-peptide 88%, urinary C-peptide expressed as nmol/l 61%, as nmol/mmol creatinine/24 h 69%, and as nmol/24 h 64%. In conclusion, post glucagon C-peptide gives a good distinction between Type 1 and Type 2 diabetes mellitus in insulin treated diabetes while 24 h urinary C-peptide gives a less sensitive distinction between the clinical types of diabetes.Keywords
This publication has 30 references indexed in Scilit:
- Sensitivity and Reproducibility of Urinary C‐peptide as Estimate of Islet B‐cell Function in Insulin‐treated DiabetesDiabetic Medicine, 1989
- Insulin Requirement in Non-insulin-dependent Diabetes Mellitus: Relation to Simple Tests of Islet B-cell Function and Insulin SensitivityDiabetic Medicine, 1988
- Reproducibility of the Glucagon TestDiabetic Medicine, 1987
- Correlations Between Fasting Plasma C-Peptide, Glucagon-Stimulated Plasma C-Peptide, and Urinary C-Peptide in Insulin-Treated DiabeticsDiabetes Care, 1987
- Residual C‐Peptide Production in Type I Diabetes Mellitus: A Comparison of Different Methods of Assessment and Influence on Glucose ControlActa Medica Scandinavica, 1983
- Lack of Effect of Improved Glycemic Control on C-Peptide Secretion in Patients Without Residual B-Cell FunctionDiabetes Care, 1982
- A Comparative Study of the Activity of Biosynthetic Human Insulin and Pork Insulin Using the Glucose Clamp Technique in Normal SubjectsDiabetes Care, 1981
- Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-peptide response to intravenous glucagonDiabetologia, 1977
- Radioimmunological determination of human C-peptide in serumDiabetologia, 1975
- Determination of total serum insulin (IRI) in insulin-treated diabetic patientsDiabetologia, 1972